Drug intelligence / Profile preview

NIDB-3002

Development stage: Preclinical
Lead developer: Discoveric Bio Beta
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Inhalation, Intravenous

Overview

NIDB-3002 is a fully human κλ IgG antibody developed by discoveric bio beta for the treatment of Gram-negative lung infections, including those associated with antimicrobial resistance. The drug acts by interfering with essential Gram-negative outer membrane processes, thereby inhibiting bacterial growth independent of host effector functions. It is currently in the discovery stage and targets infectious diseases, particularly Gram-negative bacterial infections such as *Pseudomonas aeruginosa* and cystic fibrosis-associated infections.

Beyond the preview

Go deeper on NIDB-3002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIDB-3002.

Explore the full profile